Revisit this key study during #GU25 validating that a PSA level >0.5 ng/mL after neoadjuvant ADT and before RT is prognostic and significantly associated with an increased ACM risk. 🔗 acsjournals.onlinelibrary.wiley.com/doi/full/10.10… Mutlay Sayan, MD Paul Nguyen OncoAlert

Live from UROK 2025 Turkish Rad Oncs are COOL!

UROK 2025 has just started! The Bi-annual meeting of Turkish Society for Radiation Oncology has made a great start with our international guests. Stay tuned… Sean Collins Prostate SBRT @ USF Health Simon Lo Mutlay Sayan, MD

.Harvard Radiation Oncology Program takes ESTRO 🇦🇹: Congrats to Mina Bakhtiar presenting on automated pre-treatment tumor burden imaging to predict ctDNA in #HPV oropharynx cancer & Ⓜ️ora 🩺 on #AI large language model cancer treatment information differences based on bilingual prompting

🗣️Prostate Oral Abstract #ASCO25 👉Abst5000: Dr #TedDeWeese presenting #CAN2409+prodrug +EBRT +/-ADT in Int/High Risk PCa #CAN2409 is a replication-defective adenovirus 🦠HSV-tk gene 🧬 w/ prodrug promoting immunogenic cell death ☠️ and immunize 💉against tumor antigens for

🗣️Prostate Oral Abstract #ASCO25 👉Abst5001: Dr Nick James also on @Prof-Nick-James.bsky.social presenting #MMAI for benefit from ARPI in high risk M0 PCa #STAMPEDE 🤖Multimodal AI #MMAI algorithm (ArteraAI Prostate Test v1.2) High-risk M0 STAMPEDE (w/ H&E images& clinical data) >2/3 Risk Factors (T3-4,

✨Insightful (and must-read) editorial by Mutlay Sayan, MD & Paul Nguyen in European Urology : ➡️As ADT shows modest OS benefit post-prostatectomy, the future lies in precision, leveraging PSMA PET, genomic classifiers, and AI to guide who really needs treatment intensification.

During residency, when modems crackled and PubMed barely loaded, I relied on Sem in Rad Oncol for the latest info. Contributing 2 articles to its latest issue on #prostatecancer is a full-circle moment. 🙏🏼 What Sophia Kamran, MD and Constantinos Zamboglou have put together is a masterpiece.

1️⃣ Elective Regional Nodal Irradiation in Prostate Cancer 👥 With Dr Srinivas Chilukuri, Mutlay Sayan, MD & Alan Dal Pra, MD 🎯 We cover rationale, patient selection & key trials shaping WPRT in high-risk, SBRT and post op settings. Read 📖 doi.org/10.1016/j.semr…

Congratulations to our HROP Class of 2025 - excited to see you flourish in the next step of your careers as attendings, physician scientists, and leaders in medicine, you are all wonderful! 🥲

Happy first day of #HROP residency to our beaming first-year residents!!

Excellent editorial on the DADSPORT meta-analysis: sciencedirect.com/science/articl…

What happens when GU experts tackle the toughest real-world cases together? Next at #WorldGU25, Mehmet Asim Bilen,MD (Chair), Michael Harrison, Kristen R. Scarpato, Elizabeth Kessler, MD, Mutlay Sayan, MD & John Phillips lead an unmissable session: Case-Based Therapeutic Interventions in GU Cancers –

👏 Celebrating #WorldGU25 Honored to take the stage at the World Conference on Genitourinary Cancers recently in Nashville! It was an incredible setting at the Country Music Hall of Fame and Museum and a privilege to contribute alongside so many leaders in the field. A highlight

This year's ASTRO is a big meeting for GU trials and science! I'm looking forward to hearing the results of many important GU trials such as: 🔬 Monday's 1:30 Plenary session - NRG GU005, BART 🔬 Sunday's 1:00 Clinical trials session - LUNAR, NRG GU006, NRG/RTOG 0924 🔬

Join us in celebrating our 2026 Award Recipients. 🎉 Gold Medalists: Hedvig Hricak Debra Monticciolo Honorary Fellows: Banu Atalar @Kriklund Bien Soo Tan, MD We look forward to recognizing these honorees during #ACR2026. Learn more: bit.ly/4ohTfIg

Congratulations!

A fantastic meeting filled with collaboration and new ideas. Can’t wait for next year! 🙌 World GU Conference